natgillin/translations-raw huggingface dataset:
Modigraf is a granular formulation of tacrolimus, for twice-a-day administration.
Zdravilo Modigraf je farmacevtska oblika takrolimusa v obliki zrnc, ki se jemlje dvakrat na dan.
Modigraf is used to control your body’s immune response enabling your body to accept the transplanted organ.
Zdravilo Modigraf uporabljamo za obvladovanje telesnega imunskega odziva, kar omogoči, da telo sprejme presajeni organ.
Modigraf reduces your body’s defence mechanism (immune system), which will not be as good at fighting infections.
Zdravilo Modigraf omeji vaše telesne obrambne mehanizme (imunski sistem), ki ne bodo tako dobri pri premagovanju okužb.
Modigraf should be prescribed by doctors trained to treat transplant patients and experienced in the use of medicines that control the body’s immune system (immunosuppressants).
Zdravilo Modigraf smejo predpisovati samo zdravniki, usposobljeni v zdravljenju bolnikov s presadki in izkušeni v uporabi zdravil, ki nadzorujejo imunski sistem telesa (imunosupresivi).
Modigraf therapy requires careful monitoring by adequately qualified and equipped personnel.
Zdravljenje z zdravilom Modigraf zahteva skrben nadzor ustrezno usposobljenega in opremljenega osebja.
Module 5 – Clinical
Modul 5 – Klinični
Mogilska 80
NAČIN IZDAJANJA ZDRAVILA
Mogilska 80,
Mogilska 80.
moking
kajenje;
moking cigarettes, or drinking too much alcohol
kajenje cigaret ali čezmerno pitje alkohola,
moking, or drinking too much alcohol
kajenje ali čezmerno pitje alkohola,
moking, or drinking too much alcohol,
kajenje ali čezmerno pitje alkohola,
Molecular interactions occur between corticosteroids and LABAs, whereby steroids activate the beta2- receptor gene, increasing receptor number and sensitivity and LABAs prime the glucocorticoid receptor for steroid-dependent activation and enhance cell nuclear translocation.
Med kortikosteroidi in LABA prihaja do molekulskih medsebojnih delovanj, pri čemer steroidi aktivirajo gen za beta2-receptor ter povečajo število in občutljivost receptorjev, LABA pa pripravijo glukokortikoidne receptorje na aktiviranje s steroidi in povečajo celično jedrno translokacijo.
Molecular remission at end of treatmentd
Molekularna remisija na koncu zdravljenjad
Molecular response**
citogenetičnim odzivom, število
Molecular response**
Molekularni odziv
Mometasone furoate 0.9 mg/mL
Mometazon furoat 0.9 mg/ml
Mon Tue Wed Thu Fri Sat Sun
Pon Tor Sre Cet Pet Sob Ned
MON TUE WED THU FRI SAT SUN
PON TOR SRE ČET PET SO NE
MON TUE WED THU FRI SAT SUN
PON TOR SRE ČET PET SOB NED
Mon Tue Wed Thu Fri Sat Sun
Pon Tor Sre Čet Čet Sob Ned
Mon Tue Wed Thu Fri Sat Sun
pon tor sre čet pet sob ned
MON, TUE, WED, THU, FRI, SAT, SUN
PON, TOR, SRE, ČET, PET, SOB, NED
Mon, Tue, Wed, Thu, Fri, Sat, Sun.
PON, TOR, SRE, ČET, PET, SOB, NED
Monday + Thursday
ponedeljek in četrtek
Monday Tuesday Wednesday Thursday Friday Saturday Sunday
Ponedeljek Torek Sreda Četertek Petek Sobota Nedelja
Monensin 32.4 g (equivalent to 35.2 g monensin sodium).
Monenzin 32,4 g (kar ustreza 35,2 g monenzin natrija)
Monensin binds to bacterial cell membranes and interferes with the maintenance of important ion gradients in the cell which are needed for the transport of nutrients and to generate proton-motive force.
Monenzin se veže na celične membrane bakterij in vpliva na vzdrževanje pomembnih ionskih gradientov v celici, potrebnih za transport hranil in nastajanje protonske pogonske sile.
Monepantel acts on the nematode specific nicotinic acetylcholine receptor sub-unit Hco- MPTL-1.
Monepantel deluje na podenoto Hco-MPTL-1 specifičnih nikotinskih acetilholinskih receptorjev glist.
Monitor and instruct patients on the signs and symptoms associated with hypocortisolism (e.g. weakness, fatigue, anorexia, nausea, vomiting, hypotension, hyperkalemia, hyponatraemia, hyperkalaemia or hypoglycaemia).
Bolnike spremljajte in jih poučite o znakih ter simptomih, povezanih s hipokorticizmom (npr. šibkost, utrujenost, anoreksija, navzea, bruhanje, hipotenzija, hiperkaliemija, hiponatriemija, hiperkaliemija ali hipoglikemija).
Monitor CK and serum creatinine levels weekly until resolution to baseline.
Vrednost kreatin-kinaze in kreatinina v serumu določajte enkrat na teden do znižanja na izhodiščno vrednost.
Monitor for
Alfuzosin:
Monitor for
glavnih značilnosti zdravila za
Monitor for clinical signs and symptoms of hepatic decompensation (such as ascites, hepatic encephalopathy, variceal haemorrhage).
kontrola glede kliničnih znakov in simptomov dekompenzacije jeter (kot so ascites, jetrna encefalopatija, krvavitev iz varic),
Monitor for progression or systemic symptoms until the rash is resolved.
Spremljanje morebitne razširitve ali sistemskih simptomov dokler izpuščaj ne izgine
Monitor for progression or systemic symptoms until the rash is resolved.
Spremljanje morebitne razširitve ali sistemskih simptomov dokler izpuščaj ne izgine.
Monitor liver function tests (alanine transaminase [ALT], aspartate transaminase [AST], bilirubin levels) before initiation of treatment, during each cycle of treatment, and as clinically indicated.
Nadzirati je treba rezultate testov jetrne funkcije (alanin transaminazo [ALT], aspartat transaminazo [AST], ravni bilirubina) pred začetkom zdravljenja, med vsakim ciklusom zdravljenja, in kadar je klinično indicirano.
Monitor patient for worsening of condition.
Bolnika spremljajte glede poslabšanja stanja.
Monitor patient for worsening of condition.
Spremljajte bolnike glede možnega poslabšanja stanja.
Monitor patients during and following the infusion for signs of hypersensitivity and infusion-related reactions with resuscitation equipment and appropriate medical resources readily available.
Med infundiranjem in po njem morate bolnike spremljati in biti pozorni na znake preobčutljivostnih reakcij in reakcij, povezanih z infuzijo, zagotoviti pa je treba tudi razpoložljivost ustrezne opreme in prisotnost zdravstvenega osebja za oživljanje.
Monitor patients for
Bolnike
Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis and discontinue pazopanib in patients developing ILD or pneumonitis.
Bolnike morate nadzorovati glede pljučnih simptomov, ki nakazujejo IBP/pnevmonitis in pri bolnikih, ki se jim razvija IBP ali pnevmonitis, morate zdravljenje s pazopanibom končati.
Monitor patients for signs of IMBRUVICA toxicity and follow dose modification guidance as needed.
Bolnike je treba spremljati glede znakov toksičnega delovanja zdravila IMBRUVICA in po potrebi upoštevati smernice za prilagajanje odmerjanja.
Monitor patients routinely for ophthalmologic reactions.
Bolnikom je treba oči redno kontrolirati glede morebitnih neželenih učinkov na očeh.
Monitor phenytoin concentrations.
Kontrolirajte koncentracijo fenitoina
Monitor platelet count weekly for 4 weeks following discontinuation of Revolade.
Število trombocitov je treba kontrolirati vsak teden 4 tedne po prenehanju uporabe zdravila Revolade.
Monitor such patients throughout the infusion and the post-infusion period.
Bolnike je treba opazovati med infundiranjem in v obdobju po infuziji.
Monitor the patient for 6 hours after the first dose of GILENYA has been administered for signs and symptoms of bradycardia, including hourly pulse and blood pressure checks.
Bolnika je treba 6 ur po prejemu prvega odmerka zdravila GILENYA spremljati glede znakov in simptomov bradikardije, kar vključuje merjenje frekvence pulza in krvnega tlaka vsako uro.
Monitor your blood glucose as instructed by your healthcare professional.
Preverite številko v okencu za prikaz odmerka
monitored and the dose
natančno nadzirati in njegov
monitored and the dose increased
natančno nadzirati in njegov
monitored appropriately.
spremljati.
monitored for antidepressant
treba nadzirati antidepresivni
monitored for clinical
nadzirati glede
monitored for signs of oestrogen deficiency.
klinično spremljati, da ugotovite znake pomanjkanja estrogena.
monitored when co-administering
Med sočasno uporabo s
Monitoring
premljanje
Monitoring
premljanje enkrat na
monitoring and appropriate medical
premljanje bolnika in ustrezno
Monitoring and dose adjustment
Nadzor in prilagajanje odmerka
Monitoring and laboratory tests
Nadzorovanje bolnika in laboratorijske preiskave
monitoring as appropriate.
spremljanjem bolnika.
Monitoring blood levels of these medicines may also be considered:
Zdravnik se lahko prav tako odloči za spremljanje ravni teh zdravil v krvi:
Monitoring during treatment by your doctor
Zdravniško spremljanje med zdravljenjem
Monitoring during your treatment with Starlix
Spremljanje zdravljenja z zdravilom Starlix
Monitoring for
Priporočeno je
Monitoring for adverse reactions related to oral contraceptives, in addition to those for voriconazole, is recommended
Poleg nadzora neželenih učinkov vorikonazola je priporočljiv nadzor neželenih učinkov peroralnih kontraceptivov.
Monitoring for an effect on the QTc interval is advisable and a baseline ECG is recommended prior to initiating therapy with Bosulif and as clinically indicated.
Priporoča se spremljanje vpliva na interval QTc ter preiskava EKG pred začetkom zdravljenja z zdravilom Bosulif in kadar je to klinično potrebno.
monitoring for bupropion
Priporočljivo je kontrolirati koncentracijo metadona v plazmi.
Monitoring for evidence of progressive liver disease.
Spremljanje dokazov za napredujočo jetrno bolezen
Monitoring for evidence of thromboembolism and vascular occlusion should be performed and if decreased vision or blurred vision occurs, an ophthalmic examination (including fundoscopy) should be performed.
Spremljati je treba znake trombembolije in žilne okluzije in, če se pojavi poslabšanje vida ali zamegljen vid, je treba opraviti oftalmološki pregled (vključno s fundoskopijo).
monitoring for hyperbilirubinaemia is
spremljanje bolnika (glejte poglavji 4.4
monitoring for rifabutin-associated
izpostavljenosti rifabutinu je
Monitoring for saquinavir toxicity recommended (see section 4.4)..
huda hepatocelularna toksičnost s
monitoring for signs and symptoms of thrombosis
premljanje za znake in simptome tromboze
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised.
Bolnike z znano alergijo na tienopiridine je priporočljivo kontrolirati glede znakov preobčutljivosti. .
Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised..
Bolnike z znano alergijo na tienopiridine je priporočljivo kontrolirati glede znakov preobčutljivosti.
Monitoring for signs of hypersensitivity in patients with known allergy to thienopyridines is advised.
Bolnike z znano alergijo na tienopiridine je priporočljivo kontrolirati glede znakov preobčutljivosti.
Monitoring for voriconazole- associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole (see section 4.5).
Če se vorikonazol uporablja zaporedno za flukonazolom, je priporočljiv nadzor glede neželenih učinkov, povezanih z vorikonazolom (glejte poglavje 4.5).
Monitoring for voriconazole- associated adverse reactions is recommended if voriconazole is used sequentially after fluconazole.
Če se vorikonazol uporablja zaporedno za flukonazolom, je priporočljiv nadzor glede neželenih učinkov, povezanih z vorikonazolom.
Monitoring formation of methaemoglobin (MetHb)
Nadzor nastajanja methemoglobina (MetHb)
Monitoring iron parameters
Spremljanje parametrov železa
monitoring is recommended when combined with boosted PREZISTA.
zdravilom PREZISTA je potrebna previdnost in klinično spremljanje
monitoring is recommended.
Priporočljivo je tudi klinično spremljanje bolnika.
monitoring is recommended.
spremljanje bolnika.
monitoring is warranted.
natančen klinični nadzor.
Monitoring of adverse reactions typical of statins is advised.
Priporočeno je spremljanje neţelenih učinkov, značilnih za statine.
Monitoring of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and total blood bilirubin prior to the start of and during BLINCYTO treatment especially during the first 48 hours of the first 2 cycles should be performed.
Pred začetkom zdravljenja in med zdravljenjem z zdravilom BLINCYTO je treba spremljati alanin- aminotransferazo (ALT), aspartat-aminotransferazo (AST), gamaglutamil-transferazo (GGT) in celokupni bilirubin, zlasti v prvih 48 urah prvih 2 ciklusov.
Monitoring of bone density may be indicated in patients with underlying osteoporotic bone diseases who undergo continuous therapy with filgrastim for more than 6 months.
Pri bolnikih z osteoporotično boleznijo kosti, ki se neprekinjeno zdravijo s filgrastimom dlje od 6 mesecev, je lahko indicirano spremljanje kostne gostote.
Monitoring of complete blood count is recommended prior to initiating temsirolimus therapy and periodically thereafter.
Pred začetkom zdravljenja s temsirolimusom ter v rednih intervalih med njim je priporočljivo spremljanje celotne krvne slike.
Monitoring of digoxin serum
Dokler se ne vzpostavi stanje
Monitoring of hepatic function
Nadzor delovanja jeter
Monitoring of hepatic function should be carried out in both children and adults.
Delovanje jeter je treba nadzirati tako pri otrocih kot pri odraslih.
Monitoring of hepatic tests should be done every two weeks during the first 2 months of treatment, at the 3rd month and then regularly thereafter.
Preiskave jetrne funkcije je treba narediti vsaka dva tedna prva dva meseca zdravljenja, po tretjem mesecu in nato redno.
monitoring of local and systemic
tveganja sistemskih učinkov
Monitoring of neutropenia and liver enzyme levels is recommended due to an expected increase in exposure to rifabutin.
priporoča spremljanje nevtropenije in vrednosti jetrnih encimov.
Monitoring of neutropenia and liver enzyme levels is recommended due to an expected increase in exposure to rifabutin.
Zaradi pričakovanega povečanja izpostavljenosti rifabutinu se
Monitoring of patients for renal function at baseline and during therapy with crizotinib is recommended, with particular attention to those who have risk factors or previous history of renal impairment (see section 4.8).
Na začetku zdravljenja in med zdravljenjem s krizotinibom je priporočljivo spremljanje bolnikov glede delovanja ledvic, še posebno tistih z dejavniki tveganja za okvaro ledvic ali okvaro ledvic v anamnezi (glejte poglavje 4.8).
monitoring of patients is
kliničen nadzor bolnikov.
Monitoring of patients with severe renal impairment
Spremljanje bolnikov s hudo okvaro ledvic
Monitoring of Protein loss syndrome
Nadzor sindrom izgube beljakovin
Monitoring of Protein loss syndrome
Nadzor sindroma izgube beljakovin
Monitoring of renal function is recommended as follows:
Priporočljivo je spremljanje delovanja ledvic, in sicer:
Monitoring of renal function may
Kadar se okrepljeno zdravilo
Monitoring of saquinavir plasma
Priporočljivo je spremljanje
Monitoring of saquinavir plasma concentration is recommended (see section 4.4).
Potrebno je skrbno spremljanje
monitoring of serum creatinine levels
premljanje serumske koncentracije kreatinina
monitoring of serum creatinine levels avoidance of concomitant use of loop diuretics Hypersensitivity
premljanje ravni kreatinina v serumu izogibanje sočasni uporabi diuretikov zanke.
monitoring of serum creatinine levels avoidance of concomitant use of loop diuretics.
premljanje ravni kreatinina v serumu izogibanje sočasni uporabi diuretikov zanke.
monitoring of serum creatinine levels avoidance of concomitant use of loop diuretics.
premljanje ravni kreatinina v serumu, izogibanje sočasni uporabi diuretikov zanke.
Monitoring of serum creatinine should be considered in at-risk patients.
Pri bolnikih s povečanim tveganjem je treba razmisliti o spremljanju koncentracije kreatinina v serumu.
monitoring of sirolimus
koncentracije sirolimusa v
Monitoring of small bowel, gallbladder and bile ducts, and pancreas
Nadzorovanje tankega črevesa, žolčnika in žolčevodov ter trebušne slinavke
Monitoring of stimulation cycles by ultrasound scans as well as oestradiol measurements are recommended to early identify risk factors.
Priporočeni so nadzorovanje ciklov stimulacije z ultrazvokom ter meritve estradiola za zgodnje odkrivanje dejavnikov tveganja.
Monitoring of the INR (International Normalised Ratio) value is recommended during concomitant administration with oral anticoagulants.
Med sočasno uporabo s peroralnimi antikoagulanti se priporoča spremljanje vrednosti INR (mednarodno normalizirano razmerje).
Monitoring of the patient's blood glucose during infusion is therefore recommended.
Med infundiranjem je zato priporocljivo nadziranje bolnikove glukoze v krvi.
Monitoring of the patient’s HIV therapy is also recommended.
Priporoča se spremljanje bolnikovega zdravljenja HIV.
Monitoring of the QT interval is indicated in the event of combinations of such medicinal products (see sections 4.2 and 4.4).
V primeru uporabe v kombinaciji s takimi zdravili je indicirano spremljanje dolžine intervala QT (glejte poglavji 4.2 in 4.4).
Monitoring of their renal function and plasma potassium levels is recommended before initiation and during treatment with combined therapy (see section "Contraindications").
Potreben je reden monitoring njihovega delovanja ledvic in nivo serumskega kalija pred in med zdravljenjem s kombinirano terapijo. (glej poglavje 4.3).
Monitoring of their renal function and plasma potassium levels is recommended before initiation and during treatment with combined therapy (see section 4.3).
Potreben je reden monitoring njihovega delovanja ledvic in nivoja serumskega kalija pred in med zdravljenjem s kombinirano terapijo. (glej poglavje 4.3).
monitoring of these medicinal
zdravil in zdravila EVOTAZ je
monitoring of transaminases is
elektrokardiogrami in spremljanje
monitoring of transaminases is
karbamazepina oz. fenitoina.
Monitoring of treatment – laboratory tests
Nadziranje zdravljenja – laboratorijske preiskave
monitoring of urine output
premljanje izločanja urina
monitoring of urine output
premljanje količine izločenega urina
Monitoring of viral load is recommended for these patients during the first month after switching treatment to Stribild.
Zato se pri teh bolnikih v prvem mesecu po prehodu na zdravljenje z zdravilom Stribild priporoča spremljanje virusne obremenitve.
Monitoring plasma concentrations of methadone is recommended.
Dokler se koncentracija teh zdravil v plazmi ne stabilizira, je priporočljivo pogosteje kontrolirati terapevtsko koncentracijo.
Monitoring requirements at treatment initiation
Zahtevano spremljanje bolnika ob uvedbi zdravljenja
Monitoring respiratory function during recovery:
Nadzor dihanja med popuščanjem živčnomišične blokade:
Monitoring strategy after discontinuation of TYSABRI treatment
Strategija spremljanja po prekinitvi zdravljenja z zdravilom TYSABRI
Monitoring Test
Preiskave za spremljanje bolnika
Monitoring tests
Preiskave za spremljanje
Monitoring tests
Testi za spremljanje
monitoring throughout the full
potrebno nadzorovati koncentracijo
monitoring throughout the full
spremljanje EKG-ja skozi celotno
Monitoring your EXJADE treatment
Spremljanje vašega zdravljenja z zdravilom EXJADE
Monitoring your EXJADE treatment”).
Spremljanje vašega zdravljenja z zdravilom EXJADE”).
Monitoring your Tasigna treatment
Spremljanje zdravljenja z zdravilom Tasigna
monitoring, if available, is
antiaritmikov, če so na voljo.
monitoring, if available, is
previdnost, priporočljivo pa je
Monitoring:
Spremljanje:
Monkeys administered a single bolus intravenous dose of carfilzomib at 3 mg/kg (which corresponds to 36 mg/m2 and is similar to the recommended dose in humans of 27 mg/m2 based on BSA)
Opicam, ki so dobile en intravenski bolusni odmerek 3 mg/kg karfilzomiba (kar ustreza 36 mg/m2 in je podoben na podlagi telesne površine priporočenemu odmerku 27 mg/m2 pri človeku ), so se pojavili hipotenzija, povečanje srčne frekvence in zvišanje koncentracije troponina T v serumu.
Monkeys administered ocular bimatoprost concentrations of 0.3 mg/ml daily for 1 year had an increase in iris pigmentation and reversible dose-related periocular effects characterised by a prominent upper and/or lower sulcus and widening of the palpebral fissure.
0,3 mg/ml, so opazili povečanje pigmentacije irisa in reverzibilne, z odmerkom pogojene, periokularne učinke, za katere sta bila značilna izrazit zgornji in/ali spodnji sulkus in širjenje palpebralne fisure.
Monkeys administered ocular bimatoprost concentrations of 0.3 mg/ml daily for 1 year had an increase in iris pigmentation and reversible dose-related periocular effects characterised by a prominent upper and/or lower sulcus and widening of the palpebral fissure.
0,3 mg/ml, so opazili povečanje pigmentacije irisa in reverzibilne, z odmerkom pogojene, periokularne učinke, za katerega sta bila značilna izrazita zgornji in/ali spodnji sulkus in širjenje palpebralne fisure.
Monkeys administered ocular bimatoprost concentrations of 0.3 mg/mL daily for 1 year had an increase in iris pigmentation and reversible dose-related periocular effects characterised by a prominent upper and/or lower sulcus and widening of the palpebral fissure.
0,3 mg/ml, so opazili povečanje pigmentacije irisa in reverzibilni, z odmerkom pogojene, periokularne učinke, za katere sta bila značilna izrazit zgornji in/ali spodnji sulkus in širjenje palpebralne fisure.
Monkeys administered ocular bimatoprost concentrations of 0.03% daily for 1 year had an increase in iris pigmentation and reversible dose-related periocular effects characterised by a prominent upper and/or lower sulcus and widening of the palpebral fissure.
V enoletni študiji, kjer so opice enkrat dnevno prejemale v oko bimatoprost v koncentraciji  0,03 %, so opazili povečanje pigmentacije irisa in reverzibilni, z odmerkom povezani, periokularni učinek, za katerega sta značilna trajni zgornji in/ali spodnji sulkus in širjenje palpebralne fisure.
Mono- therapy
Mono- terapija
Mono- therapy
Mono-terap ija
Mono/diglycerides of caprylic/capric acid Polyglycerol oleate
monogliceridi in digliceridi kaprilne in kaprinske kisline, poliglicerol oleat,
Monoamine oxidase (MAO) inhibitors
Zaviralci monoaminooksidaze (MAO)
Monoamine oxidase inhibitors
Zaviranje monoaminooksidaze
Monoamine oxidase inhibitors (MAOI)
Zaviralci monoaminooksidaze (zaviralci MAO)
Monoamine oxidase inhibitors (MAOI) (used to treat depression).
zaviralce monoaminooksidaze (zaviralce MAO) (za zdravljenje depresij),
Monoamine oxidase inhibitors (MAOIs) – for depression.
Zaviralce monoaminooksidaze (zaviralci MAO) – za depresijo.
Monoamine oxidase inhibitors (MAOIs): You should not take ARICLAIM if you are taking, or have recently taken (within the last 14 days) an antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Zaviralci monoaminooksidaze (MAOI): zdravila ARICLAIM ne smete jemati, če jemljete ali ste v zadnjih 14 dneh vzeli antidepresivno zdravilo, imenovano zaviralec monoaminooksidaze (MAOI).
Monoamine oxidase inhibitors (MAOIs): You should not take Cymbalta if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Zaviralci monoaminooksidaze (MAOI): Zdravila Cymbalta ne smete jemati, če jemljete ali ste v zadnjih 14 dneh vzeli drugo antidepresivno zdravilo, imenovano zaviralec monoaminooksidaze (MAOI).
Monoamine oxidase inhibitors (MAOIs): You should not take Duloxetine Lilly if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Zaviralci monoaminooksidaze (MAOI): Zdravila Duloxetine Lilly ne smete jemati, če jemljete ali ste v zadnjih 14 dneh vzeli drugo antidepresivno zdravilo, imenovano zaviralec monoaminooksidaze (MAOI).
Monoamine oxidase inhibitors (MAOIs): You should not take Duloxetine Zentiva if you are taking, or have recently taken (within the last 14 days) another antidepressant medicine called a monoamine oxidase inhibitor (MAOI).
Zaviralci monoaminooksidaze (MAOI): Zdravila Duloksetin Zentiva ne smete jemati, če jemljete ali ste v zadnjih 14 dneh vzeli drugo antidepresivno zdravilo, imenovano zaviralec monoaminooksidaze (MAOI).